My work and career | Bill Gates

When I first got involved with Alzheimer’s back in 2017, my expectation for what we would achieve was very modest. A number of high-profile trials for new drugs had failed, and the process for diagnosing someone—either a PET scan or a spinal tap—was costly and time-consuming. The problem was scale: not enough people diagnosed early enough, not enough people in clinical trials, not enough data sharing to learn more.

I thought the research field could do a bit better if it had more resources, but I’m completely blown away by just how much it’s improved. The progress we’ve made is amazing to me.